MedTrace Logo

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

NCT06359275 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2024-06-25

No results posted yet for this study

Summary

This trial is a phase II clinical trial of the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR radiotherapy in patients with locally advanced unresectable pancreatic cancer and patients with only local recurrence after pancreatic cancer surgery, to observe the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR in the treatment of patients with locally advanced unresectable pancreatic cancer.

Conditions

Interventions

DRUG

PD-1

Toripalimab，240 mg/time，D1， Q3W

DRUG

Nab-paclitaxel

Nab-paclitaxel, 125mg/m2，IV，D1，8, Q3W

DRUG

Gemcitabine

Gemcitabine，1000mg/m2，IV，D1，8，Q3W

RADIATION

PULSAR

5-10 Gy per session, a total of 5 times.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Weijing Zhang · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-12-31
Completion
2027-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06359275 on ClinicalTrials.gov